Skip to main content
TipRanks
Go Ultimate75% OFF

Kane Biotech (KNE) Stock Price & Analysis

2 Followers

KNE Stock Chart & Stats

CA$0.03CA$0.00(0.00%)
At close: 4:00 PM EST
C$0.02C$0.025C$0.03C$0.035Aug 17Aug 31Sep 14Sep 28Oct 13Oct 26Nov 9
Day’s Range
CAD 0.03 - CAD 0.03
52-Week Range
CAD 0.02 - CAD 0.05
Previous Close
CAD 0.03
Volume
N/A
Average Volume (3M)
53.42K
Market Cap
CAD 6.15M
Enterprise Value
CAD 7.26M
Total Cash (Recent Filing)
CAD 854.73K
Total Debt (Recent Filing)
CAD 1.96M
Price to Earnings (P/E)
―
Beta
0.64
Next Earnings
Nov 26, 2026 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Diversified Antibiofilm Platform

Kane’s antibiofilm technologies address several end markets rather than relying on one use case. This application breadth creates multiple avenues for commercialization and gives the company a platform from which successful formulations or products could support longer-term expansion.

Debt Reduction

Reducing total debt provides a modest improvement in financial flexibility and may lessen future interest or refinancing pressure. Although the balance sheet remains stressed, continued debt reduction can help preserve resources for operations and product commercialization over the next several quarters.

Improved Free Cash Flow Burn

The improvement in free cash flow versus 2025 indicates some movement toward better cash discipline, even though outflows remain substantial. If sustained, lower cash burn could extend the company’s operating runway and reduce the urgency of external funding for near-term activities.

Bears Say

Collapsing Revenue

Extremely low and declining revenue indicates that current commercial traction is insufficient to support the operating base. Persistent contraction reduces internally generated funding, limits reinvestment capacity, and makes the company more dependent on a successful recovery in product sales.

Severely Negative Margins

Margins at these levels show that current revenue is far below the cost required to deliver products and operate the business. Without a substantial improvement in pricing, sales scale, or cost structure, profitability is unlikely to become self-sustaining over the next several quarters.

Negative Equity And Solvency Pressure

A growing equity deficit is a significant balance-sheet weakness because liabilities exceed reported assets. It limits financial flexibility and raises the likelihood that future operations or investment could require refinancing or equity issuance, potentially constraining strategic choices.

Kane Biotech News

KNE FAQ

What was Kane Biotech’s price range in the past 12 months?
Kane Biotech lowest stock price was C$0.02 and its highest was C$0.05 in the past 12 months.
What is Kane Biotech’s market cap?
Kane Biotech’s market cap is C$6.15M.
When is Kane Biotech’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Kane Biotech’s earnings last quarter?
Kane Biotech released its earnings results on Aug 27, 2026. The company reported -C$0.004 earnings per share for the quarter.
Is Kane Biotech overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Kane Biotech pay dividends?
Kane Biotech does not currently pay dividends.
What is Kane Biotech’s EPS estimate?
Kane Biotech’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kane Biotech have?
Kane Biotech has 205,056,560 shares outstanding.
What happened to Kane Biotech’s price movement after its last earnings report?
Kane Biotech reported an EPS of -C$0.004 in its last earnings report. Following the earnings report the stock price went up 20%.
Which hedge fund is a major shareholder of Kane Biotech?
Currently, no hedge funds are holding shares in TSE:KNE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology